KNSA 240816 25.00C (KNSA240816C25000) Stock Options, News & Quotes

US OptionsDetailed Quotes

KNSA240816C25000

Watchlist

1.00
-0.03-2.91%

15min DelayClose Aug 16 16:00 ET

1.10High1.00Low

Intraday

5D
Daily

News

Roth MKM Says Small-Cap Value Reaches Key Technical Support, Lists 14 "Bullish" Stocks
Seeking AlphaAug 12 11:34 ET
New Strong Buy Stocks for August 1st
Zacks Aug 1 06:25 ET
Express News | Kiniksa Pharmaceuticals Ltd : JP Morgan Raises Target Price to $38 From $30
ReutersAug 1 01:34 ET
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $578,966, According to a Recent SEC Filing
MT NewswiresJul 26 08:34 ET
Kiniksa Pharmaceuticals International(KNSA.US) Officer Sells US$3.49 Million in Common Stock
Moomoo NewsJul 25 16:36 ET
Kiniksa Pharmaceuticals International | 10-Q: Q2 2024 Earnings Report
SEC announcementJul 25 16:16 ET · Announcements

Comments

TrendTrader

Jul 23 11:19

Looking for 30

$Kiniksa Pharmaceuticals International (KNSA.US)$

Moomoo AI

Feb 28 07:16

The share price rise is a fair reaction to the company's revenue growth. More gains could follow if the trend continues. Yet, consider the company's profitability and cash flow before investing.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Delivers Shareholders Respectable 66% Return Over 1 Year, Surging 4.7% in the Last Week Alone

Moomoo AI

Jan 23 06:38

Kiniksa Pharmaceuticals' low P/S ratio may be due to its forecast growth being lower than the industry. Shareholders accept this, conceding future revenue probably won't surprise positively. It's hard to see the share price rising strongly soon under these circumstances.

Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Low P/S No Reason For Excitement

Meltyy

Jan 3 06:11

Upcoming Ph 2 readouts in Q1 2024…

$Cellectar BioSciences (CLRB.US)$ Phase 2
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2...

Moomoo AI

Dec 8, 2023 10:12

Kiniksa Pharmaceuticals' growing cash burn is offset by substantial cash reserves & signs of business growth. The firm can issue shares or borrow cheaply to fund further growth.

We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn